AstraZeneca to discover drugs with U.K. cancer groups

AstraZeneca pledged about $6.3 million for a drug-development deal with Cancer Research Technology and the Institute of Cancer Research in the U.K. The three-year joint venture will focus on molecular chaperones, which were found to support the survival of cancer cells.

View Full Article in:

Telegraph (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL